Stephen Huhn, M.D., FACS, FAAPThis morning we have about 20 or 21 Slides to go through and as Martin said I’ll have some brief remarks in the first few slides and then I’m going to have Dr. Curt go through the interim data in more detail and then we’ll finish up with a Q&A at the end. The Phase I/II study design, just to remind everyone is an open label clinical investigation dealing with a single dose and a fixed dose of the human central nervous system stem cell which is delivered directly into the spinal cord at a dose of 20 million cells.
StemCells, Inc. CEO Discusses Interim 6-Month Data From Spinal Cord Injury Trial - Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts